Global provider continues to expand analytical service capabilities for life science companies developing advanced treatments for cancer and rare diseases

KAISERAUGST, Switzerland, May 6, 2024 /PRNewswire/ -- Solvias announced today that it is expanding its global network of laboratory testing centers with a new biotech site in Research Triangle Park, N.C. It is the company's latest investment to expand its analytical testing services supporting life science organizations with the growing number of cell and gene therapies (CGTs) and biologics in use and under development.

The 50,000-square-foot facility, expected to be completed in 2025 and bring 170+ jobs to the Raleigh-Durham area, will serve as Solvias' North American hub for large molecule analytical services. It will offer critical cell-based potency assays, advanced Next-Gen Sequencing (NGS) capabilities, and related testing services supporting multiple biologic modalities. From the outset, the new testing center will support characterization and release testing of CGT and other advanced therapies, including Adeno-Associated virus (AAV) gene therapies, mRNA therapies and antibody drug conjugates.

Noting that the global CGT and advanced biologics market is expected to maintain a double-digit annual growth rate over the next ten years, Archie Cullen, CEO of Solvias, said: "Our new center strongly complements our biologics and CGT sites in Europe and expands our world-class testing capabilities in the U.S. Our team is thrilled to bring our newest center of excellence to Research Triangle Park, a leading research and development center and burgeoning hub for the life science industry. We will continue to invest in expanding our capabilities to support our customers with their critical work of developing and maintaining life-changing therapies."

Solvias' new facility expands its global footprint to six centers of excellence. It is the company's second site in the U.S., where it supports life science organizations with analytical testing. The new center will feature state-of-the-art analytical instrumentation, laboratory automation technology and integrated digital management systems.

About Solvias
Solvias is a global provider of chemistry, manufacturing, and control (CMC) analytics to the life science industry. Its team of scientists combine years of experience with regulatory understanding across small molecules, biologics, and cell and gene therapies. The company offers comprehensive solutions from raw materials to drug products to final release testing, as well as API development and manufacturing for small molecules. Headquartered near Basel, Switzerland, Solvias operates five global centers of excellence to the highest standards and in accordance with ISO, GMP, GLP and FDA regulations. For more information, visit solvias.com.

Photo - https://mma.prnewswire.com/media/2404289/Solvias_Cell_and_Gene_Therapy_Center_of_Excellence_in_North_America.jpg
Photo - https://mma.prnewswire.com/media/2404290/Archie_Cullen_on_Solvias_new_Cell_and_Gene_Therapy_Center.jpg
Logo - https://mma.prnewswire.com/media/2321760/solvias_logo_2clr_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/solvias-to-build-biologics-and-cell--gene-therapy-testing-center-in-research-triangle-park-302135605.html

Images

Tags

More Like This

Solvias Opens Center of Excellence for Biologics and Cell & Gene Therapy in Research Triangle Park

Solvias to Perform Release Testing on World's First CRISPR-based Gene-Editing Therapy

Immunovia streamlines lab operations with move to Research Triangle Park, North Carolina

Immunovia's new lab staffed and operational after rapid implementation

Tsingke Shines at Cell & Gene Therapy International 2024

Minaris Advanced Therapies Opens New State-of-the-Art GMP Facility to Support Global Cell and Gene Therapy Growth

Solvias Earns Strong First Assessment from EcoVadis

TATAA Biocenter Achieves GLP Accreditation for qPCR and dPCR